Similarly, the large percentage of patients with hypertension undertaking angiotensin-converting enzyme inhibitors (ACEIs) or ARBs is a remarkable characteristic among those presenting severe COVID-19 manifestations. This evidence concerns the gene ACE and COVID-19.